NASDAQ:SLXN
Silexion Therapeutics Corp
Silexion Therapeutics Corp reported net income of −$11.9M in fiscal 2025. Free cash flow was −$10.8M, and the diluted share count rose 3093.3%.Summary generated from Silexion Therapeutics Corp's SEC filings. Latest annual report filed Mar 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$10.8M
FCF marginn/a
Share count change+3093.3%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | n/a | n/a | n/a |
| Operating income | −5 | −13 | −12 |
| Net income | −5 | −17 | −12 |
| Free cash flow | −5 | −8 | −11 |
Recent filings
- DEF 14AProxy statement
Oct 5, 2026 - 8-KRegulation FD disclosure
Sep 30, 2026 - 8-KEntry into a material agreement
Sep 29, 2026 - 8-KRegulation FD disclosure
Sep 28, 2026 - 8-KNotice of delisting or listing-rule failure
Sep 25, 2026 - 8-KResults of a shareholder vote
Sep 25, 2026 - DEF 14AProxy statement
Aug 24, 2026 - 8-KNotice of delisting or listing-rule failure
Aug 21, 2026